Patent 7858312 was granted and assigned to Duke University on December, 2010 by the United States Patent and Trademark Office.
The present invention relates to bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using α1d-adrenergic receptor (α1dAR) antagonists. The invention further relates to a method of screening compounds for their ability to serve as α1dAR selective antagonists.